We observed somatic mutations or fusions in NF2 in 41% (7/17) of meningiomas, 5% (3/60) of ependymomas, and 25% (3/12) of schwannomas, as well as rare fusions in ERBB4, YAP1, and/or QKI in 10% (6/60) of ependymomas. This evidence concerns the gene YAP1 and ependymoma.